111, Inc.
111, Inc. (YI) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
yi · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Pharmaceuticals · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
111, Inc.You YI | $43M | N/A | — | -$8.58 |
 Annovis Bio, Inc. ANVS | $36M | N/A | — | -$1.40 |
 Celularity Inc. CELU | $19M | N/A | — | -$3.59 |
 Dyadic International, Inc. DYAI | $25M | N/A | — | -$0.23 |
 electroCore, Inc. ECOR | $80M | N/A | — | -$1.65 |
 Elutia Inc. ELUT | $46M | 0.54x | — | $1.29 |
 NeuroOne Medical Technologies Corporation NMTC | $30M | N/A | — | -$0.54 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for 111, Inc. (YI) measures how much investors pay for each dollar of the company's trailing earnings. YI's current PE ratio of N/A is calculated by dividing its stock price of $4.91 by its TTM earnings per share of -$8.58.
Frequently asked questions
YI pe ratio · 6 questionsYI's current PE ratio is N/A as of 2026-06-09, based on a stock price of $4.91 and TTM EPS of -$8.58. Data sourced from Financial Modeling Prep via YI's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · 111, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09